Professional Health Print Ad Spend Through February 2017
Advertising spend in professional health print journals reached $82 million during February 2017 according to Kantar Media’s Healthcare data. Although this is down 15% compared to the same time period in 2016, the discrepancy in ad spending is smaller than it was the previous month
, implying an upward tick in spend from January to February 2017.
GlaxoSmithKline (GSK) continued to rank number one for pharma companies spending in professional health print journals during the month of February. Lilly made its way into the top five after falling to number six in January. The pharma company lead the way throughout all of 2016, but appears to be spending lighter this year.
The Breo Ellipta Inhaler from GSK was the top spending drug for the second month in a row. Jardiance increased spend for time period by the largest margin compared to the same time period last year. With increases of this magnitude, the drug could potentially be on pace to overtake the number one spot this year.
Through the end of February, a total of 12,196 ad pages were purchased in professional health print journals. Inhaled Steroids have seen consistent increases in spend so for 2017, but Antineoplastic Agents (cancer therapy drugs) have been holding steady as the number one ranking drug class for both dollars and pages.
Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in professional healthcare. This analysis is part of ongoing healthcare reporting we release on a monthly basis. Make sure to check back next month for the most recent data, or contact us
to learn more!